tiprankstipranks
Nektar Therapeutics (GB:0UNL)
LSE:0UNL
UK Market
0UNL
Nektar Therapeutics
RESEARCH TOOLSreports

Nektar Therapeutics (0UNL) Share Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

0UNL Analyst Ratings

Strong Buy
9Ratings
Strong Buy
7 Buy
2 Hold
0 Sell
Based on 9 analysts giving stock ratings to
Nektar
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

0UNL Stock 12 Month Forecast

Average Price Target

$143.43
▲(99.71% Upside)
Based on 9 Wall Street analysts offering 12 month price targets for Nektar Therapeutics in the last 3 months. The average price target is $143.43 with a high forecast of $192.00 and a low forecast of $65.00. The average price target represents a 99.71% change from the last price of $71.82.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"28":"$28","193":"$193","69.25":"$69.3","110.5":"$110.5","151.75":"$151.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":192,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$192.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":143.42857142857142,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$143.43</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":65,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$65.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[28,69.25,110.5,151.75,193],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,72,81.23076923076923,90.46153846153845,99.6923076923077,108.92307692307692,118.15384615384615,127.38461538461539,136.6153846153846,145.84615384615384,155.07692307692307,164.3076923076923,173.53846153846155,182.76923076923077,{"y":192,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,72,77.49450549450549,82.98901098901099,88.48351648351648,93.97802197802197,99.47252747252747,104.96703296703296,110.46153846153845,115.95604395604394,121.45054945054945,126.94505494505493,132.43956043956044,137.93406593406593,{"y":143.42857142857142,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,72,71.46153846153847,70.92307692307692,70.38461538461539,69.84615384615384,69.3076923076923,68.76923076923077,68.23076923076923,67.6923076923077,67.15384615384616,66.61538461538461,66.07692307692308,65.53846153846153,{"y":65,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":29.1,"date":1756674000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.288,"date":1759266000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.172,"date":1761948000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60.195,"date":1764540000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.079,"date":1767218400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.894,"date":1769896800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68,"date":1772316000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.669,"date":1774990800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":86.84,"date":1777582800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.795,"date":1780261200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.45,"date":1782853200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.629,"date":1785531600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72,"date":1788210000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$192.00Average Price Target$143.43Lowest Price Target$65.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
J.P. Morgan Analyst forecast on GB:0UNL
Jessica Fye
J.P. Morgan
J.P. Morgan
$65
Hold
-9.50%
Downside
Initiated
08/21/26
Nektar reinstated with a Neutral at JPMorganNektar reinstated with a Neutral at JPMorgan
Piper Sandler Analyst forecast on GB:0UNL
Yasmeen Rahimi
Piper Sandler
Piper Sandler
$192
Buy
167.34%
Upside
Reiterated
08/20/26
Piper Sandler Remains a Buy on Nektar Therapeutics (NKTR)
Canaccord Genuity Analyst forecast on GB:0UNL
Edward Nash
Canaccord Genuity
Canaccord Genuity
$153
Buy
113.03%
Upside
Reiterated
08/17/26
Nash Reiterates Buy on Nektar, Citing Strong Cash Position and Rezpegaldesleukin Progress; Keeps $153 Price Target Unchanged
H.C. Wainwright Analyst forecast on GB:0UNL
Arthur He CFA
H.C. Wainwright
H.C. Wainwright
$185
Buy
157.59%
Upside
Reiterated
08/17/26
Nektar: Strong Cash Runway and Rezpeg Momentum Support Unchanged $185 Price Target and Buy Rating
Wedbush Analyst forecast on GB:0UNL
Martin Fan
Wedbush
Wedbush
$80
Hold
11.39%
Upside
Reiterated
08/14/26
Analysts Offer Insights on Healthcare Companies: Gossamer Bio (NASDAQ: GOSS), Nektar Therapeutics (NASDAQ: NKTR) and Aprea Therapeutics (NASDAQ: APRE)
William Blair Analyst forecast on GB:0UNL
Andy Hsieh
William Blair
William Blair
―
Buy
―
Reiterated
08/14/26
Analysts Offer Insights on Healthcare Companies: Nektar Therapeutics (NASDAQ: NKTR), Aveanna Healthcare Holdings (NASDAQ: AVAH) and GoodRx Holdings (NASDAQ: GDRX)
Citi Analyst forecast on GB:0UNL
Samantha Semenkow
Citi
Citi
$151
Buy
110.25%
Upside
Reiterated
08/14/26
Nektar: Rezpeg’s Advancing Phase 3 Programs and Disease‑Modifying Potential Support Buy/High Risk Rating with Price Target Maintained at $151
BTIG Analyst forecast on GB:0UNL
Julian Harrison
BTIG
BTIG
$178
Buy
147.84%
Upside
Reiterated
08/13/26
Analysts' Top Healthcare Picks: Nektar Therapeutics (NKTR), Kodiak Sciences (KOD)
TD Cowen Analyst forecast on GB:0UNL
Marc Frahm
TD Cowen
TD Cowen
―
Buy
―
Reiterated
08/13/26
Nektar Therapeutics Initiated at Buy on Rezpeg’s Advancing Pivotal Programs and Solid Cash Runway
Oppenheimer Analyst forecast on GB:0UNL
Jay Olson
Oppenheimer
Oppenheimer
$140
Buy
94.93%
Upside
Reiterated
05/08/26
Oppenheimer Remains a Buy on Nektar Therapeutics (NKTR)
B. Riley Securities Analyst forecast on GB:0UNL
Mayank Mamtani
B. Riley Securities
B. Riley Securities
$105→$150
Buy
108.86%
Upside
Reiterated
02/23/26
Nektar price target raised to $150 from $105 at B. RileyNektar price target raised to $150 from $105 at B. Riley
Jefferies Analyst forecast on GB:0UNL
Roger Song
Jefferies
Jefferies
$121
Buy
68.48%
Upside
Reiterated
12/17/25
Jefferies Sticks to Its Buy Rating for Nektar Therapeutics (NKTR)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
J.P. Morgan Analyst forecast on GB:0UNL
Jessica Fye
J.P. Morgan
J.P. Morgan
$65
Hold
-9.50%
Downside
Initiated
08/21/26
Nektar reinstated with a Neutral at JPMorganNektar reinstated with a Neutral at JPMorgan
Piper Sandler Analyst forecast on GB:0UNL
Yasmeen Rahimi
Piper Sandler
Piper Sandler
$192
Buy
167.34%
Upside
Reiterated
08/20/26
Piper Sandler Remains a Buy on Nektar Therapeutics (NKTR)
Canaccord Genuity Analyst forecast on GB:0UNL
Edward Nash
Canaccord Genuity
Canaccord Genuity
$153
Buy
113.03%
Upside
Reiterated
08/17/26
Nash Reiterates Buy on Nektar, Citing Strong Cash Position and Rezpegaldesleukin Progress; Keeps $153 Price Target Unchanged
H.C. Wainwright Analyst forecast on GB:0UNL
Arthur He CFA
H.C. Wainwright
H.C. Wainwright
$185
Buy
157.59%
Upside
Reiterated
08/17/26
Nektar: Strong Cash Runway and Rezpeg Momentum Support Unchanged $185 Price Target and Buy Rating
Wedbush Analyst forecast on GB:0UNL
Martin Fan
Wedbush
Wedbush
$80
Hold
11.39%
Upside
Reiterated
08/14/26
Analysts Offer Insights on Healthcare Companies: Gossamer Bio (NASDAQ: GOSS), Nektar Therapeutics (NASDAQ: NKTR) and Aprea Therapeutics (NASDAQ: APRE)
William Blair Analyst forecast on GB:0UNL
Andy Hsieh
William Blair
William Blair
―
Buy
―
Reiterated
08/14/26
Analysts Offer Insights on Healthcare Companies: Nektar Therapeutics (NASDAQ: NKTR), Aveanna Healthcare Holdings (NASDAQ: AVAH) and GoodRx Holdings (NASDAQ: GDRX)
Citi Analyst forecast on GB:0UNL
Samantha Semenkow
Citi
Citi
$151
Buy
110.25%
Upside
Reiterated
08/14/26
Nektar: Rezpeg’s Advancing Phase 3 Programs and Disease‑Modifying Potential Support Buy/High Risk Rating with Price Target Maintained at $151
BTIG Analyst forecast on GB:0UNL
Julian Harrison
BTIG
BTIG
$178
Buy
147.84%
Upside
Reiterated
08/13/26
Analysts' Top Healthcare Picks: Nektar Therapeutics (NKTR), Kodiak Sciences (KOD)
TD Cowen Analyst forecast on GB:0UNL
Marc Frahm
TD Cowen
TD Cowen
―
Buy
―
Reiterated
08/13/26
Nektar Therapeutics Initiated at Buy on Rezpeg’s Advancing Pivotal Programs and Solid Cash Runway
Oppenheimer Analyst forecast on GB:0UNL
Jay Olson
Oppenheimer
Oppenheimer
$140
Buy
94.93%
Upside
Reiterated
05/08/26
Oppenheimer Remains a Buy on Nektar Therapeutics (NKTR)
B. Riley Securities Analyst forecast on GB:0UNL
Mayank Mamtani
B. Riley Securities
B. Riley Securities
$105→$150
Buy
108.86%
Upside
Reiterated
02/23/26
Nektar price target raised to $150 from $105 at B. RileyNektar price target raised to $150 from $105 at B. Riley
Jefferies Analyst forecast on GB:0UNL
Roger Song
Jefferies
Jefferies
$121
Buy
68.48%
Upside
Reiterated
12/17/25
Jefferies Sticks to Its Buy Rating for Nektar Therapeutics (NKTR)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ONCBeOne Medicines
DNLIDenali Therapeutics
SNDXSyndax Pharmaceuticals
ZYMEZymeworks
PTGXProtagonist Therapeutics
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Nektar Therapeutics

3 Months
Arthur He CFAH.C. Wainwright
Success Rate
10/18 ratings generated profit
56%
Average Return
+35.44%
Copying Arthur He CFA's trades and holding each position for 3 Months would result in 55.56% of your transactions generating a profit, with an average return of +35.44% per trade.
1 Year
Yasmeen RahimiPiper Sandler
Success Rate
13/14 ratings generated profit
93%
Average Return
+191.14%
Copying Yasmeen Rahimi's trades and holding each position for 1 Year would result in 92.86% of your transactions generating a profit, with an average return of +191.14% per trade.
2 Years
Yasmeen RahimiPiper Sandler
Success Rate
13/14 ratings generated profit
93%
Average Return
+215.37%
Copying Yasmeen Rahimi's trades and holding each position for 2 Years would result in 92.86% of your transactions generating a profit, with an average return of +215.37% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0UNL Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
13
10
9
11
11
Buy
8
3
2
2
2
Hold
3
2
1
2
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
24
15
12
15
15
In the current month, 0UNL has received 13 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. 0UNL average Analyst price target in the past 3 months is 143.43.
Each month's total comprises the sum of three months' worth of ratings.

0UNL Financial Forecast

0UNL Earnings Forecast

Next quarter’s earnings estimate for 0UNL is -$2.13 with a range of -$3.07 to -$1.78. The previous quarter’s EPS was -$1.23. 0UNL beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0UNL has Performed in-line its overall industry.
Next quarter’s earnings estimate for 0UNL is -$2.13 with a range of -$3.07 to -$1.78. The previous quarter’s EPS was -$1.23. 0UNL beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0UNL has Performed in-line its overall industry.

0UNL Sales Forecast

Next quarter’s sales forecast for 0UNL is $10.41M with a range of $9.54M to $12.00M. The previous quarter’s sales results were $10.13M. 0UNL beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0UNL has Performed in-line its overall industry.
Next quarter’s sales forecast for 0UNL is $10.41M with a range of $9.54M to $12.00M. The previous quarter’s sales results were $10.13M. 0UNL beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0UNL has Performed in-line its overall industry.

0UNL Stock Forecast FAQ

What is GB:0UNL’s average 12-month price target, according to analysts?
Based on analyst ratings, Nektar Therapeutics’s 12-month average price target is 143.43.
    What is GB:0UNL’s upside potential, based on the analysts’ average price target?
    Nektar Therapeutics has 99.71% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Nektar Therapeutics a Buy, Sell or Hold?
          Nektar Therapeutics has a consensus rating of Strong Buy, which is based on 7 buy ratings, 2 hold ratings and 0 sell ratings.
            What is Nektar Therapeutics’s share price target?
            The average share price target for Nektar Therapeutics is 143.43. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is $192.00 ,and the lowest forecast is $65.00. The average share price target represents 99.71% Increase from the current price of $71.82.
              What do analysts say about Nektar Therapeutics?
              Nektar Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.
                How can I buy shares of Nektar Therapeutics?
                To buy shares of GB:0UNL, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.